Biomarker evaluation of skeletal muscle toxicity following clofibrate administration in rats

Research paper by Karen Bodié, Wayne R. Buck, Julia Pieh, Michael J. Liguori, Andreas Popp

Indexed on: 29 Mar '16Published on: 25 Mar '16Published in: Experimental and Toxicologic Pathology


The use of sensitive biomarkers to monitor skeletal muscle toxicity in preclinical toxicity studies is important for the risk assessment in humans during the development of a novel compound. Skeletal muscle toxicity in Sprague Dawley Rats was induced with clofibrate at different dose levels for 7 days to compare standard clinical pathology assays with novel skeletal muscle and cardiac muscle biomarkers, gene expression and histopathological changes. The standard clinical pathology assays aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) enzyme activity were compared to novel biomarkers fatty acid binding protein 3 (Fabp3), myosin light chain 3 (Myl3), muscular isoform of CK immunoreactivity (three isoforms CKBB, CKMM, CKMB), parvalbumin (Prv), skeletal troponin I (sTnI), cardiac troponin T (cTnT), cardiac troponin I (cTnI), CKMM, and myoglobin (Myo). The biomarker elevations were correlated to histopathological findings detected in several muscles and gene expression changes. Clofibrate predominantly induced skeletal muscle toxicity of type I fibers of low magnitude. Useful biomarkers for skeletal muscle toxicity were AST, Fabp3, Myl3, (CKMB) and sTnI. Measurements of CK enzyme activity by a standard clinical assay were not useful for monitoring clofibrate-induced skeletal muscle toxicity in the rat at the doses used in this study.

Figure 10.1016/j.etp.2016.03.001.0.jpg
Figure 10.1016/j.etp.2016.03.001.1.jpg
Figure 10.1016/j.etp.2016.03.001.2.jpg
Figure 10.1016/j.etp.2016.03.001.3.jpg
Figure 10.1016/j.etp.2016.03.001.4.jpg

More like this: